RBC Capital Resumes Coverage of Danaher Corporation (DHR)

Danaher Corporation (NYSE:DHR) is one of the best medical stocks to invest in according to billionaires. RBC Capital resumed coverage of Danaher Corporation (NYSE:DHR) with an Outperform rating on May 14, setting a price target of $200. The firm told investors in a research note that it sees the company’s growth recovering with an improvement in the bioprocess market. It further added that factors like the lapping of “idiosyncratic headwinds”, a sustained bioprocess rebound, and end market improvement put the company’s 6% revenue growth target within reach for 2027.

For reference, in its financial results for fiscal Q1 2026, Danaher Corporation (NYSE:DHR) reported net earnings of $1.0 billion, or $1.45 per diluted common share. Revenues for the quarter rose 3.5% year-over-year to $6.0 billion, while non-GAAP core revenue grew 0.5% year-over-year. The company also reported that operating cash flow was $1.3 billion, while non-GAAP free cash flow was $1.1 billion.

Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, industrial, and commercial products and services, making it a significant diagnostics stock. It operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.